Movement Alert｜Twist Bioscience Corp Falls 6.14% in Regular Trading, Earnings Expectations and Lilly TuneLab Collaboration Stay in Focus

Market Focus11-10 22:33

On November 10, Twist Bioscience Corp fell 6.14% in Regular Trading, trading at $127.0 per share, with turnover of $8.393 million.

The move coincided with continued market trading around the company’s upcoming November 12 earnings report, AI drug discovery order expectations, and progress tied to its previously disclosed antibody characterization data services collaboration for Eli Lilly’s TuneLab platform.

Current market expectations point to quarterly revenue of about $123 million, up 25.96% year over year, with adjusted EPS expected at a loss of $0.37 to $0.44 per share, reflecting a narrowing loss trend. Separate market commentary also noted that institutional sentiment remains broadly constructive, with an average target price near $150.33, even as short-term trading volatility has remained elevated ahead of the report.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment